Abstract:Amyotrophic Lateral Sclerosis (ALS) is a motor neurodegenerative disorder whose cellular hallmarks are the progressive death of motor neurons (MNs) located in the anterior horn of the spinal cord, brainstem and motor cortex, and the formation of intracellular protein aggregates. Over the course of the disease, progressive paralysis takes place, leading to patient death within 3–5 years after the diagnosis. Despite decades of intensive research, only a few therapeutic options exist, with a limited benefit on the disease progression. Preclinical animal models have been very useful to decipher some aspects of the mechanisms underlying ALS. However, discoveries made using transgenic animal models have failed to translate into clinically meaningful therapeutic strategies. Thus, there is an urgent need to find solutions to discover drugs that could impact on the course of the disease, with the ultimate goal to extend the life of patients and improve their quality of life. Induced pluripotent stem cells (iPSCs), similarly to embryonic stem cells (ESCs), have the capacity to differentiate into all three embryonic germ layers, which offers the unprecedented opportunity to access patient-specific central nervous system cells in an inexhaustible manner. Human MNs generated from ALS patient iPSCs are an exciting tool for disease modelling and drug discovery projects, since they display ALS-specific phenotypes. Here, we attempted to review almost 2 decades of research in the field, first highlighting the steps required to efficiently generate MNs from human ESCs and iPSCs. Then, we address relevant ALS studies which employed human ESCs and iPSC-derived MNs that led to the identification of compounds currently being tested in clinical trials for ALS. Finally, we discuss the potential and caveats of using patient iPSC-derived MNs as a platform for drug screening, and anticipate ongoing and future challenges in ALS drug discovery.

Stem Cell Models and Gene Targeting for Human Motor Neuron Diseases

Induced Pluripotent Stem Cells: Ex Vivo Models for Human Diseases Due to Mitochondrial DNA Mutations

Stem Cells for the Treatment of Neurodegenerative Diseases

Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs

The Potential of Induced Pluripotent Stem Cells to Test Gene Therapy Approaches for Neuromuscular and Motor Neuron Disorders

Human stem cell models of neurodegeneration: From basic science of amyotrophic lateral sclerosis to clinical translation

Human-induced pluripotent stem cells: potential for neurodegenerative diseases

Progress and Challenges of Cell Replacement Therapy for Neurodegenerative Diseases Based on Direct Neural Reprogramming

Harnessing the Potential of Human Pluripotent Stem Cell-Derived Motor Neurons for Drug Discovery in Amyotrophic Lateral Sclerosis: From the Clinic to the Laboratory and Back to the Patient

ALS, a cellular whodunit on motor neuron degeneration

Experimental Cell Models for Investigating Neurodegenerative Diseases

Progress and challenges in directing the differentiation of human iPSCs into spinal motor neurons

Spinal Muscular Atrophy Modeling and Treatment Advances by Induced Pluripotent Stem Cells Studies

Spinal Cord Organoids to Study Motor Neuron Development and Disease

Advances, challenges and future directions for stem cell therapy in amyotrophic lateral sclerosis

Modeling neurodegenerative diseases with patient-derived induced pluripotent cells: Possibilities and challenges

CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis

iPSC-based disease modeling and drug discovery in cardinal neurodegenerative disorders

Induced Pluripotent Stem Cells for Disease Modeling and Drug Discovery in Neurodegenerative Diseases

Human Stem Cell Models of Polyglutamine Diseases: Sources for Disease Models and Cell Therapy

[iPS cell technologies toward overcoming neurological diseases]